Overview

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

Status:
RECRUITING

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

Phase:

PHASE3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

dulaglutide